The clinical candidates pharma execs are tracking

Industry leaders at JPM this week revealed which up-and-coming assets they’re watching from other companies in oncology and neuroscience.

By Meagan Parrish • Jan. 16, 2026

It’s crunch time for US biopharma M&A. Can drugmakers strike deals despite persisting anxieties?

The “trauma” faced by pharma execs in 2025 kept M&A at a low simmer, experts say, but as predictability returns, dealmaking could be turned up.

By Michael Gibney • Jan. 15, 2026

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

A biotech’s snakebite pill is drawing the US military’s interest

Backed by the Department of Defense, Ophirex is developing the first oral snakebite treatment, making on-the-ground treatment possible for the first time.

By Alexandra Pecci • Jan. 13, 2026

3 positive trends for Massachusetts’ biopharma sector

Despite a rocky landscape for the biotech industry nationally, Massachusetts has shown innovation growth and stronger funding than expected, which could bode well for the future.

By Michael Gibney • Jan. 13, 2026

What Sanofi’s multiple sclerosis troubles could mean for the space

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug class. 

By Kelly Bilodeau • Jan. 12, 2026

PharmaVoice’s Crystal Ball: What’s next for AI and drug R&D

Industry execs foresee drug innovation and AI breakthroughs in 2026.

By Meagan Parrish • Jan. 9, 2026

Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?

The entrepreneur’s cancer institute is striving to be the financial glue for an embattled research community while going beyond therapies and creating cures.

By Michael Gibney • Jan. 8, 2026

5 FDA drug approvals to watch in 2026

Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this year.

By Alexandra Pecci • Jan. 7, 2026

PharmaVoice’s Crystal Ball: Market and policy forces shaping the industry

How pharma leaders believe the regulatory and investment market landscape will change in 2026. 

By Meagan Parrish • Jan. 6, 2026

3 of China’s most innovative pharma companies

The top Chinese drugmakers succeeding in both innovation and business savvy.

By Kelly Bilodeau • Jan. 5, 2026

Biogen’s CIO is betting on a tech and AI overhaul to ‘pave the highways’ toward growth

Guy Hadari discusses how his role has changed with the introduction of new technologies, and what that means for Biogen’s future.

By Michael Gibney • Dec. 19, 2025

The leading GLP-1 contenders in pharma’s race for an obesity pill

Recent mid-stage readouts reveal how the market for an oral weight loss drug could take shape. 

By Alivia Kaylor • Dec. 18, 2025

3 key takeaways from the FDA’s new animal testing guidance

The agency’s moves to end animal testing are “not a fluke.” Here’s what drugmakers need to know about where it goes from here.

By Alexandra Pecci • Dec. 17, 2025

After years of debate, the Biosecure Act could be headed for Trump’s desk

The revised version of the bill softens compliance burdens between U.S. pharma firms and Chinese suppliers, but still has teeth.

By Kelly Bilodeau • Dec. 15, 2025

Amylyx pins its next hopes on a niche drug in the obesity space

A lot is riding on Amylyx’s late-stage candidate for post-bariatric hypoglycemia.

By Meagan Parrish • Dec. 12, 2025

Pharma’s top deals in 2025

The year’s three largest acquisitions signal where pharma is willing to pay big for promising candidates.

By Michael Gibney • Dec. 11, 2025

Will 2026 be pharma’s M&A breakout year?

Big Pharma needs new products to replenish pipelines and has plenty of money in the coffers, but looming uncertainties could stymie dealmaking again.

By Kelly Bilodeau • Dec. 10, 2025

How Lilly uses Big Pharma heft to lift up-and-coming biotechs

With great power comes great responsibility, and Eli Lilly is employing financial success and technical know-how to give smaller biotechs a leg up.

By Michael Gibney • Dec. 9, 2025

Along with NIH cuts come risks to patient safety and scientific data

The abrupt withdrawal of research funds affected 74,000 clinical trial participants, including some already taking the drugs being studied.

By Kelly Bilodeau • Nov. 26, 2025

What’s next in the eye disease pipeline?

An early gene therapy breakthrough spurred investments, but can the industry maintain momentum?  

By Kelly Bilodeau • Nov. 24, 2025

Amylin could reign supreme in the next wave of obesity drugs

With investment in amylin analogs on the rise for weight management, three key candidates are inching closer to critical readouts.

By Alivia Kaylor • Nov. 18, 2025

The next leap in Alzheimer’s R&D is coming, but not around the corner

While a couple drugs have reached the market, their effects are still modest, and experts say a true paradigm shift is still a ways off.

By Kelly Bilodeau • Nov. 17, 2025

RNAi looked doomed to fail — until Alnylam’s science chief found a way

Kevin Fitzgerald, Alnylam Pharmaceuticals’ chief scientific officer, reveals the hard times that led to RNAi success, and what it takes to pave new roads in biotech.

By Michael Gibney • Nov. 13, 2025

Why Pfizer and Novo are duking it out over weight loss startup Metsera

A brutal bidding war between two industry giants over a clinical-stage drugmaker is a sign of the weight loss arena’s high stakes.

By Michael Gibney • Nov. 6, 2025

Chinese drugmaker becomes top trial sponsor — and other clinical trends

The industry’s top indication areas for R&D and other shifts in the clinical trial landscape last year.

By Kelly Bilodeau • Nov. 5, 2025